Arkolith/Insider Trading/SRNEQ/Form 4

Ji Henry

See Remarks, DirectorSorrento Therapeutics, Inc. (SRNEQ) · full profile →Form 4 · filed Mar 20, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 17, 2023Option exercise(X)20K$0.80$16K20K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 17, 2023Disposed to issuer(D)195—$00

Transaction Codes

X
Exercise of in-the-money derivative
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899243-23-009159) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML